With some observers saying that the future of HIV-drug profits looks shaky, what’s a pharma to do? Charge more? Not if the AIDS Treatment Activist Coalition (ATAC) can help it: The group cried foulwhen it learned that the newly approved protease inhibitor Aptivus(tipranavir) was priced at $13,000 a year, making it the most expensivePI ever. At press time, the drug’s maker, Boehringer-Ingelheim, hadn’tyet officially responded to the ATAC attack.